Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points We’re reiterating our Overweight rating on shares of LHX post last week’s 2Q earnings report, but we’re lowering our target price to adopt a more normalized valuation post ......
Key Points Q2’26 EBITDA and EPS beat on PEM segment strength Management’s near-term commentary mixed We rate WLK shares Overweight with a 12-month target price of USD110 Summary Westlake Corporation ......
Key Points We’re raising our top- and bottom-line forecasts for RBC after Friday’s 1QFY27 earnings report, and we’re reiterating our Overweight rating on the shares. We’ve raising our target price ......
Key Points Q2’26 EBITDA and EPS beat on O&P strength Near-term outlook commentary mixed We rate LYB shares Overweight with a 12-month target price of USD83 per share Summary LyondellBasell ......
Key Points Q1’26 EBITDA beat. Q3’26 guidance mid-point below consensus EBITDA expansion observed in all three segments (y-o-y). Management commentary mixed We rate HUN shares Overweight with a 12-month target ......
Key Points Q2’26 EBITDA beat on sequential margin expansion across all three segments Below consensus Q3’26 guidance partly driven by VCM facility outage We rate Olin shares Overweight with a ......